AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...
The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...
MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...
Women in England are set to gain new, taxpayer-funded tests for endometriosis after NICE recommended them for regular use. | ...
As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...
Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s ...
Caidya and Simbec-Orion have united to create a new platform aimed at helping drug development programs accelerate and scale.
Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates (ADCs) using ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results